






KRIBIOLISA™ Anti-Adalimumab (HUMIRA™) ELISA

REF : KBI2015

Ver 3.0


RUO

Enzyme Immunoassay for the quantitative determination of Anti-Adalimumab in serum, plasma and cell culture supernatant

RUO	For Research Use Only	REF	Catalog Number
	Store At	LOT	Batch Code
	Manufactured By		Biological Risk
	Expiry Date		Consult Operating Instructions

For Research Purposes Only. Purchase does not include or carry the right to resell or transfer this product either as a stand-alone product or as a component of another product. Any use of this product other than the permitted use without the express written authorization of KRISHGEN BioSystems is strictly prohibited.

REF KBI2015

 96 tests



KRISHGEN BioSystems

For US / Europe: toll free +1(888)-970-0827 tel: +1(562)-568-5005

For Asia / India: tel: +91(22)-49198700

Email: sales@krishgen.com

Introduction:

Adalimumab, sold under the trade name Humira among others, is a medication used to treat rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, chronic psoriasis, hidradenitis suppurativa, and juvenile idiopathic arthritis. In rheumatoid arthritis, adalimumab has a response rate similar to methotrexate, and in combination, it nearly doubles the response rate of methotrexate alone.


Adalimumab is a TNF-inhibiting, anti-inflammatory, biologic medication. It binds to tumor necrosis factor-alpha (TNF α), which normally binds to TNF α receptors, leading to the inflammatory response of autoimmune diseases. By binding to TNF α , adalimumab reduces this inflammatory response. Because TNF α is also part of the immune system, which protects the body from infection, treatment with adalimumab may increase the risk of infections.

Intended Use:

The KRIBIOLISA™ Anti-Adalimumab ELISA is used as an analytical tool for quantitative determination of Anti-Adalimumab in serum, plasma and cell culture supernatant.

Principle:

The method employs the quantitative sandwich enzyme immunoassay technique. A commercially available Adalimumab is pre-coated onto microwells. Samples and Standards are pipetted into microwells and antibodies to Adalimumab present in the sample are bound by the capture antibody. Then, a HRP (horseradish peroxidase) conjugated Adalimumab is pipette and incubated simultaneously with samples. After washing microwells in order to remove any non-specific binding, the ready to use substrate solution (TMB) is added to microwells and color develops proportionally to the amount of Anti-Adalimumab in the sample. Color development is then stopped by addition of stop solution. Absorbance is measured at 450 nm.

**Materials Provided:**

Part	Description	Qty
Adalimumab Coated Microtiter Plate	96 well polystyrene microplate (12 strips of 8 wells) coated with a monoclonal antibody specific for human IL-6.	1 x 96 wells
Anti-Adalimumab Standard	Recombinant Anti-Adalimumab in a buffered protein base with 10% human serum and preservative sodium azide < 0.01% – Standards: 0, 10, 20, 40, 80, 160, 320 and 640 ng/ml.	8 x 0.5 ml
Adalimumab:HRP Conjugate	Recombinant Adalimumab conjugated to horseradish peroxidase with protein stabilizer and preservatives 0.02% methylisothiazolone and 0.02% bromonitrodioxane.	12 ml
Sample Diluent	Buffered protein base with preservative thiomersol < 0.01%	50 ml
(20X) Wash Buffer	25 ml/vial of a 20-fold concentrated solution of buffered surfactant with preservative thiomersol < 0.01%. May turn yellow over time.	25 ml
TMB Substrate	12 ml/vial of stabilized chromogen	12 ml
Stop Solution	12 ml/vial of 2N sulfuric acid	12 ml
Instruction Manual		1 no

Materials to be provided by the End-User:

1. Microtiter Plate Reader able to measure absorbance at 450 nm.
2. Adjustable pipettes and multichannel pipettor to measure volumes ranging from 25ul to 1000ul
3. Deionized (DI) water
4. Wash bottle or automated microplate washer
5. Standard (mm/mm) graph paper or software for data analysis
6. Timer
7. Absorbent Paper

Handling/Storage:

1. All reagents should be stored at 2°C to 8°C for stability.
2. All the reagents and wash solutions should be used within 12 months from manufacturing date.
3. Before using, bring all components to room temperature (18-25°C). Upon assay completion ensure all components of the kit are returned to appropriate storage conditions.
4. The Substrate is light-sensitive and should be protected from direct sunlight or UV sources.

Health Hazard Warnings:

1. Reagents that contain preservatives may be harmful if ingested, inhaled or absorbed through the skin.
2. For Research use only.

Sample Preparation and Storage:

Blood is taken by venipuncture. Serum is separated after clotting by centrifugation. Plasma can be used, too. Lipaemic, hemolytic or contaminated samples should not be run. Repeated freezing and thawing should be avoided. If samples are to be used for several assays, initially aliquot samples and keep at -20°C.

For Cell Culture Supernatant - If necessary, centrifuge to remove debris prior to analysis. Samples can be stored at -20°C or -80°C. Avoid repeated freeze-thaw cycles.

Preparation Before Use:

Allow samples to reach room temperature prior to assay. Take care to agitate patient samples gently in order to ensure homogeneity.

Serum and Plasma Test Sample preparation - Samples have to be diluted 1:10 (v/v), e.g. for 1:10 (5 ul sample + 45 ul sample diluent) prior to assay. The samples may be kept at 2 - 8°C for up to three days. Long-term storage requires -20°C.

Reagent Preparation (all reagents should be diluted immediately prior to use):

1. Label any aliquots made with the kit Lot No and Expiration date and store it at appropriate conditions mentioned.
2. Bring all reagents to Room temperature before use.
3. To make Wash Buffer (1X); dilute 25 ml of 20X Wash Buffer in 475 ml of DI water.

Procedural Notes:

1. In order to achieve good assay reproducibility and sensitivity, proper washing of the plates to remove excess un-reacted reagents is essential.
2. High Dose Hook Effect may be observed in samples with very high concentrations of Anti-Adalimumab. High Dose Hook Effect is due to excess of antibody for very high concentrations of Anti-Adalimumab present in the sample. High Dose Hook effect is most likely encountered from samples early in the purification process.

If Hook Effect is possible, the samples to be assayed should be diluted with a compatible diluent. Thus if the Anti-Adalimumab concentration of the undiluted sample is less than the diluted sample, this may be indicative of the Hook Effect.

3. Avoid assay of Samples containing sodium azide (NaN₃), as it could destroy the HRP activity resulting in under-estimation of the amount of Anti-Adalimumab.
4. It is recommended that all Standards and Samples be assayed in duplicates.
5. Maintain a repetitive timing sequence from well to well for all the steps to ensure that the incubation timings are same for each well.
6. If the Substrate has a distinct blue color prior to use it may have been contaminated and use of such substrate can lead to compromise of the sensitivity of the assay.
7. The plates should be read within 30 minutes after adding the Stop Solution.
8. Make a work list in order to identify the location of Standards and Samples.

Assay Procedure:

1. It is strongly recommended that all Standards and Samples be run in duplicates. A standard curve is required for each assay. All steps must be performed at 37°C
2. Pipette **100 ul** of **Standards** or **Samples** into the respective wells
3. Cover the plate and incubate for 60 minutes at 37°C
4. Aspirate and wash plate 4 times with **Wash Buffer (1X)** and blot residual buffer by firmly tapping plate upside down on absorbent paper. Wipe of any liquid from the bottom outside of the microtiter wells as any residue can interfere in the reading step.
5. Pipette **100 ul** of **Adalimumab:HRP Conjugate** into the respective wells.
6. Cover the plate and incubate for 60 minutes at 37°C.
7. Aspirate and wash plate 4 times with **Wash Buffer (1X)** same as in step 4.
8. Add **100 ul** of **TMB Substrate** in each well.
9. Incubate the plate at 37°C for 30 minutes in dark. DO NOT SHAKE or else it may result in higher backgrounds and worse precision. Positive wells should turn bluish in color.
10. Pipette out **100 ul** of **Stop Solution**. Wells should turn from blue to yellow in color.
11. Read the absorbance at 450 nm with a microplate reader.

Calculation of Results:

Determine the Mean Absorbance for each set of duplicate or triplicate Standards and Samples. Using Semi-Log graph paper, plot the average value (absorbance 450 nm) of each standard on the Y-axis versus the corresponding concentration of the standards on the X-axis. Draw the best fit curve through the standard points. To determine the unknown Anti-Adalimumab concentrations, find the unknown's Mean Absorbance value on the Y-axis and draw a horizontal line to the standard curve. At the point of intersection, draw a vertical line to the X-axis and read the Anti-Adalimumab Concentration. If samples were diluted, multiply by the appropriate dilution factor.

Software which is able to generate a cubic spline curve-fit or a polynomial curve (2nd order) is best recommended for automated results.

Note:


It is recommended to repeat the assay at a different dilution factor in the following cases:

- If the sample absorbance value is below the first standard.
- If the absorbance value is equivalent or higher than the 640 ng/ml standard.

Typical Data

Standard Concentration (ng/ml)	Abs A	Abs A	Mean Abs	Interpolated Concentration	% Interpolated Concentration against Actual Concentration
0	0.060	0.057	0.059	--	--
10	0.089	0.075	0.082	12.0	120.1
20	0.109	0.101	0.105	21.0	105.2
40	0.189	0.181	0.185	44.6	111.4
80	0.302	0.295	0.299	71.4	89.2
160	0.802	0.758	0.780	165.3	103.3
320	1.521	1.619	1.570	317.9	99.4
640	2.725	2.810	2.768	640.6	100.1

Typical Graph

**Quality Control:**

It is recommended that for each laboratory assay appropriate quality control samples in each run to be used to ensure that all reagents and procedures are correct.

Performance Characteristics of the Kit:

This kit has been validated as per EMA/FDA guidelines in line with ICH Code for Harmonization of Biological Assays.

Sensitivity:

Limit Of Detection: It is defined as the lowest detectable concentration corresponding to a signal of Mean of '0' standard plus 2* SD.

10 replicates of '0' standards were evaluated and the LOD was found to be less than 8 ng/ml

Specificity:

The antibodies used in the kit are monoclonal antibodies, anti-idiotypic and specific for Anti- Adalimumab. The calibrators / standards used are calibrated against commercially source.

Linearity:

Standards provided in the kit will be used for measuring the linearity range of Anti-Adalimumab present in matrix.

Precision:

Precision is defined as the percent coefficient of variation (%CV) i.e. standard deviation divided by the mean and multiplied by 100.

Assay precision was determined by both intra (n=5 assays) and inter assay (n=5 assays) reproducibility on two pools with low (10 ng/ml), medium (80 ng/ml) and high (640 ng/ml) concentrations.

While actual precision may vary from laboratory to laboratory and technician to technician, it is recommended that all operators achieve precision below these design goals before reporting results.

Pool	Intra Assay %CV	Inter Assay %CV
Low	<10%	<10%
Medium	<5%	<5%
High	<5%	<5%

Safety Precautions:

- **This kit is for Research Use only.** Follow the working instructions carefully.
- The expiration dates stated on the kit are to be observed. The same relates to the stability stated for reagents
- Do not use or mix reagents from different lots.
- Do not use reagents from other manufacturers.
- Avoid time shift during pipetting of reagents.
- All reagents should be kept in the original shipping container.
- Some of the reagents contain small amount of sodium azide (< 0.1 % w/w) as preservative. They must not be swallowed or allowed to come into contact with skin or mucosa.
- Source materials maybe derived from human body fluids or organs used in the preparation of this kit were tested and found negative for HBsAg and HIV as well as for HCV antibodies. However, no known test guarantees the absence of such viral agents. Therefore, handle all components and all patient samples as if potentially hazardous.
- Since the kit contains potentially hazardous materials, the following precautions should be observed
 - Do not smoke, eat or drink while handling kit material
 - Always use protective gloves
 - Never pipette material by mouth
 - Wipe up spills promptly, washing the affected surface thoroughly with a decontaminant.
- In any case GLP should be applied with all general and individual regulations to the use of this kit.




SCHEMATIC ASSAY PROCEDURE

1. Remove all components, 30 minutes before adding into the assay plate.



2. Avoid repeated cool-thaw of the components as there will be a loss of activity and this can affect the results.



3. Pipette **100 ul Standards / Samples** into each well.

4. Cover plate and incubate for at 37°C.

5. Aspirate and wash wells 4 times with **Wash Buffer (1X)**.

6. Pipette **100 ul Adalimumab:HRP Conjugate** into each well.

7. Cover plate and incubate for at 37°C.

8. Aspirate and wash wells 4 times with **Wash Buffer (1X)**.

9. Pipette **100 ul TMB Substrate** into each well.

10. Cover plate and incubate for at 37°C.

11. Pipette **100 ul Stop Solution** into each well.

12. Read absorbance at 450nm with a microplate reader within of stopping reaction.

Typical Example of a Work list

Well #	Contents	Absorbance at 450nm	Mean Absorbance	ng/ml Anti-Adalimumab equivalent
1A 2A	zero std zero std			
1B 2B	10 ng/ml 10 ng/ml			
1C 2C	20 ng/ml 20 ng/ml			
1D 2D	40 ng/ml 40 ng/ml			
1E 2E	80 ng/ml 80 ng/ml			
1F 2F	160 ng/ml 160 ng/ml			
1G 2G	320 ng/ml 320 ng/ml			
1H 2H	640 ng/ml 640 ng/ml			
1I 2I	Sample Sample			

References:

Detection of adalimumab and anti-adalimumab levels by ELISA: clinical considerations.
B Marinari, E Botti, M Bavetta... - Drug development ..., 2014 - Wiley Online Library

Relationship between the clinical response to adalimumab treatment and serum levels of adalimumab and anti-adalimumab antibodies in patients with psoriatic ...
AWR van Kuijk, M de Groot, SO Stapel... - Annals of the ..., 2010 - ard.bmj.com

Development of a universal anti-adalimumab antibody standard for interlaboratory harmonization
A Gils, NV Castele, R Poppe... - Therapeutic drug ..., 2014 - ncbi.nlm.nih.gov

Using monoclonal antibodies as an international standard for the measurement of anti-adalimumab antibodies
PA van Schouwenburg, S Kruihof, G Wolbink... - ... of pharmaceutical and ..., 2016 - Elsevier

Validation of a drug-resistant anti-adalimumab antibody assay to monitor immunogenicity in the presence of high concentrations of adalimumab

Surprising negative association between IgG1 allotype disparity and anti-adalimumab formation: a cohort study
GM Bartelds, E de Groot, MT Nurmohamed... - Arthritis research & ..., 2010 - Springer

Comparative Evaluation of 4 Commercially Available ELISA Kits for Measuring Adalimumab and Anti-adalimumab Antibodies
MJ Sam, SJ Connor, WWS Ng... - Therapeutic Drug ..., 2020 - journals.lww.com

LIMITED WARRANTY

Krishgen Biosystems does not warrant against damages or defects arising in shipping or handling, or out of accident or improper or abnormal use of the Products; against defects in products or components not manufactured by Krishgen Biosystems, or against damages resulting from such non-Krishgen Biosystems made products or components. Krishgen Biosystems passes on to customer the warranty it received (if any) from the maker thereof of such non Krishgen made products or components. This warranty also does not apply to Products to which changes or modifications have been made or attempted by persons other than pursuant to written authorization by Krishgen Biosystems.












THIS WARRANTY IS EXCLUSIVE. The sole and exclusive obligation of Krishgen Biosystems shall be to repair or replace the defective Products in the manner and for the period provided above. Krishgen Biosystems shall not have any other obligation with respect to the Products or any part thereof, whether based on contract, tort, and strict liability or otherwise. Under no circumstances, whether based on this Limited Warranty or otherwise, shall Krishgen Biosystems be liable for incidental, special, or consequential damages.

This Limited Warranty states the entire obligation of Krishgen Biosystems with respect to the Products. If any part of this Limited Warranty is determined to be void or illegal, the remainder shall remain in full force and effect.

Krishgen Biosystems. 2021

THANK YOU FOR USING KRISHGEN PRODUCT!

SYMBOLS KEY

	Adalimumab Microtiter Plate (12x8 wells)
	Anti-Adalimumab Standard
	Conjugate Horseradish Peroxidase
	Sample Diluent
	(20X) Wash Buffer
	TMB Substrate
	Stop Solution
	Consult Instructions for Use
	Catalog Number
	Expiration Date
	Storage Temperature